incretin is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Take anticoagulants ('blood thinners') such as warfarin (Coumadin), diabetes medications, digoxin (Lanoxin), theophylline (Theobid, Theo-Dur), and vitamins Have ever had any blood disease, such as decreased white blood cells (leukopenia), decreased platelets (thrombocytopenia) or aplastic anemia, or liver disease (hepatitis, jaundice)
A total of 100 cities across six continents were part of the 100 Resilient Cities program funded by the Rockefeller Foundation. In January 2016, the United States Department of Housing and Urban Development announced winners of its National Disaster Resilience Competition (NDRC), awarding three 100RC member cities – New York City; Norfolk, VA; and New Orleans, LA – with more than $437 million in disaster resilience funding. The grant was the largest ever received by the city of Norfolk. In April 2019, it was announced that the foundation would no longer be funding the 100 Resilient Cities program as a whole. Some elements of the initiative's work, most prominently the funding of several cities' Chief Resilience Officer roles, continues to be managed and funded by the Rockefeller Foundation, while other aspects of the program continue in the form of two independent organizations, Resilient Cities Catalyst (RCC) and the Global Resilient Cities Network (GRCN), founded by former 100RC leadership and staff.
Rather than introducing an inactivated or attenuated microorganism to an immune system (which would constitute a "whole-agent" vaccine), a subunit vaccine uses a fragment of it to create an immune response. One example is the subunit vaccine against hepatitis B, which is composed of only the surface proteins of the virus (previously extracted from the blood serum of chronically infected patients but now produced by recombination of the viral genes into yeast). Other examples include the Gardasil virus-like particle human papillomavirus (HPV) vaccine, the hemagglutinin and neuraminidase subunits of the influenza virus, and edible algae vaccines. A subunit vaccine is being used for plague immunization.
== Distribution == The species is found in Central Asia, the Caucasus Mountains, and northeastern Africa. It can be found throughout the area of Afghanistan, Azerbaijan, Egypt, India, Iran, Iraq, Israel, Jordan, Kashmir, Libya, Palestine, Pakistan, Saudi Arabia, Sudan, the United Arab Emirates, Russia (adventive) and the United States (adventive).
Steroids are named after the sterol cholesterol which was first described in gall stones from Ancient Greek chole- 'bile' and stereos 'solid'. Gonane, also known as steran or cyclopentanoperhydrophenanthrene, the nucleus of all steroids and sterols, is composed of seventeen carbon atoms in carbon-carbon bonds forming four fused rings in a three-dimensional shape. The three cyclohexane rings (A, B, and C in the first illustration) form the skeleton of a perhydro derivative of phenanthrene. The D ring has a cyclopentane structure. When the two methyl groups and eight carbon side chains (at C-17, as shown for cholesterol) are present, the steroid is said to have a cholestane framework. The two common 5α and 5β stereoisomeric forms of steroids exist because of differences in the side of the largely planar ring system where the hydrogen (H) atom at carbon-5 is attached, which results in a change in steroid A-ring conformation. Isomerisation at the C-21 side chain produces a parallel series of compounds, referred to as isosteroids. Examples of steroid structures are:
Sources: en.wikipedia.org
=== Voting rights === During his 2022 gubernatorial campaign, Moore said he opposed voter-ID legislation introduced by state senator Justin Ready, calling it "voter suppression". In September 2022, Moore said he opposed a lawsuit filed by his Republican opponent, state delegate Dan Cox, against the Maryland State Board of Elections to block the early counting of Maryland's mail-in ballots in the 2022 elections, alleging that Cox was trying to sow distrust and uncertainty in the electoral system. The Maryland Court of Appeals unanimously rejected Cox's arguments to halt early mail-in ballot tabulation in October 2022. In April 2023, Moore signed a bill to allow counties to begin counting mail-in ballots before Election Day. Before this bill was enacted, Maryland was the only state that restricted the processing of absentee ballots until after Election Day, according to the National Conference of State Legislatures. In April 2026, Moore signed the Maryland Voting Rights Act into law, which allows challenges to counties or municipalities that hold elections in a way that dilutes the votes cast by minority voters. He also criticized the U.S. Supreme Court's ruling in Louisiana v. Callais, which he said would lead to decreased minority representation in Congress. Moore has criticized the use of closed primaries in elections, including Maryland's, saying that they disenfranchise voters and should be "reevaluated".
== Further reading == Davies, Catherine, and Richard John Miron. PRF in Facial Esthetics. Batavia, IL: International Quintessence Publishing Group. 2020. Sachdev, Mukta, and Niti Khunger. Essentials for Aesthetic Dermatology in Ethnic Skin. CRC Press, 29 May 2023. Zoe Kececioglu Draelos. Cosmetic Dermatology: Products and Procedures. Chichester, West Sussex; Hoboken, Nj, John Wiley & Sons, Inc, 2016. Wilfried Rähse, and Wiley-Vch. Cosmetic Creams: Development, Manufacture and Marketing of Effective Skin Care Products. Weinheim Wiley-Vch, 2020.
== India retail reforms == Until 2011, Indian central government denied foreign direct investment (FDI) in multi-brand Indian retail, forbidding foreign groups from any ownership in supermarkets, convenience stores or any retail outlets, to sell multiple products from different brands directly to Indian consumers. The government of Manmohan Singh, prime minister, announced on 24 November 2011 the following:
== Co-culture composition and conditions == Based on the desired product of the SCOBY, different species of bacteria and yeast are used. Such cultures generally include aerobic, gram negative AAB species such as Acetobacter, Gluconobacter and Komagataeibacter, aerobic, gram positive LAB such as Lactobacillus, as well as various yeasts such as Saccharomyces and Zygosaccharomyces. Strains are pre-screened for viability under compatible conditions, increased yield of desired product, and indisposition to compete; once chosen, various culture conditions are modified for optimal growth and productivity. For kombucha SCOBYs, the first step is yeast fermentation of sugars such as glucose from black or green tea into ethanol and carbon dioxide. Zygosaccharomyces is reported to be involved in 84.1% of all kombucha SCOBY fermentation processes due to its improved stability in high sugar and halophilic conditions, while Saccharomyces is predominantly used for its efficient fermentation rates and resistance to high temperature and alcohol content. Different variations of yeast can also be added as either a supplemental means to introduce different flavors and aromas or ensure reaction completion by utilizing different niches. While these niches vary yeast to yeast, certain fermentation conditions remain consistent. Such conditions include but are not limited to high substrate concentration, sufficient oxygen levels, temperatures of 20–30 °C (68–86 °F), and a pH between 4–4.5.
=== Glass fiber filters === Glass fiber filter has the pore size of 1 μm, it is useful for filtering highly contaminated solutions or difficult-to-filter solution. Also, glass fiber filter has extends filter life, wide range of particulate loads and can prevent sample contamination. In addition, different types of glass fiber filter are suitable for different filtration situation. There are 7 different types of glass fiber filters and the major difference is thickness.
Sources: en.wikipedia.org
== Coronary collateralization == Coronary collateralization exists latently in the normal heart. Microscopic collateral vessels of the heart undergo a process called transformation that widens the vessel lumen at the expense of its cell wall in response to myocardial stresses—specifically, myocardial spasm and hypoxia secondary to myocardial infarction or acutely stressful exercise. The status of the coronary collaterals has also been shown to be influenced by the presence of diabetes mellitus. The functional significance of the coronary collateral vessels is a matter of continuing experimental investigation although their existence has been known for over three centuries and been documented repeatedly in man and beast over the past seven decades. Although a now-classic series of experiments by Schaper in the late 1960s and '70s expanded our understanding of the mechanisms by which these usually redundant, microscopic (40-10 um in diameter in their native state) ur-arterioles are transformed by ischemia or stenosis into vessels with life-preserving blood capacity, equally as many studies have denied the function of these vessels to preserve myocardium by salvaging tissue perfusion and maintaining blood pressure as have documented this.
=== Pharmacokinetics === In the field of pharmacokinetics, steady state refers to the condition in which the rate of drug administration is balanced by the rate of drug elimination, resulting in a stable concentration of the drug in the bloodstream over time. This equilibrium typically occurs following repeated dosing or continuous infusion, and is used to ensure consistent therapeutic drug levels. For most drugs exhibiting first-order kinetics, steady state is generally achieved after approximately four to five half-lives, at which point the changes in plasma concentrations between doses become minimal and predictable. At steady state, drug concentrations do not remain at a single, unchanging value but rather fluctuate within a limited range bounded by peak (Cmax) and trough (Cmin) values across each dosing interval. Ideally, this range is maintained above the minimum effective (therapeutic) concentration and below the threshold for adverse effects, thereby achieving concentrations within the so-called therapeutic window.
space. The boundaries of the shaded regions in the figure are the boundaries of stability in the two directions (also known as boundaries of bands). The domain of overlap of the two regions is the trapping domain. For calculation of these boundaries and similar diagrams as above see Müller-Kirsten.
Non-steroidal anti-inflammatory drug (NSAID) can compete with loop diuretics for organic ion transporters, thus preventing the diuretic molecules from being secreted into the proximal convoluted tubules. Those with diuretic resistance, cardiorenal syndrome, and severe right ventricular dysfunction may have better response to continuous diuretic infusion. Diuretic dosages is adjusted to produce 3 to 5 litres of urine per day. Thiazide (blockade of sodium-chloride symporter), amiloride (blockade of epithelial sodium channels) and carbonic anhydrase inhibitors (blockade of chloride-bicarbonate exchanger pendrin) has been suggested to complement the action of loop diuretics in resistance cases but limited evidence are available to support their use.
==== Native Hawaiian or other Pacific Islander ==== The obesity rate for Native Hawaiian or other Pacific Islander adults (over 30 BMI) in the US in 2015 was 33.4%. No breakdown by sex was given for Native Hawaiian or other Pacific Islander adults in the CDC figures.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.